Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioma × rindopepimut × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 3 Neoplasms 2 Gliosarcoma 2 Brain Neoplasms 2 Recurrence 1 Glioma 1

Interventions

Temozolomide 28 Bevacizumab 10 Radiotherapy 9 Surgical Procedures, Operative 6 Lomustine 6 IL13-PE38 6 Carboplatin 6 TIC10 compound 5 vorasidenib 4 trametinib 4 dabrafenib 4 Flucytosine 4 Dianhydrogalactitol 4 Chlorotoxin 4 vocimagene amiretrorepvec 3 Radiation 3 Paclitaxel 3 OKN 007 3 Irinotecan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cyclophosphamide 3 CLR1404 3 trans-sodium crocetinate 2 pembrolizumab 2 marizomib 2 lenvatinib 2 enzastaurin 2 contrast agent BR1 2 avapritinib 2 abemaciclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00458601 2018-01-16

ACT III

Celldex Therapeutics

Phase 2 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡